| Literature DB >> 33314936 |
Wei Zheng1,2, Zhen Wang1, Xiangrui Jiang1, Qingjie Zhao1, Jingshan Shen1,2.
Abstract
Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH remains a severe clinical condition, and the long-term survival of patients with PAH is still suboptimal. Thus, potential therapeutic targets and new agents to treat PAH are urgently needed. In recent years, a variety of related pathways and potential therapeutic targets have been found, which brings new hope for PAH therapy. In this perspective, not only are the marketed drugs used to treat PAH summarized but also the recently developed novel pharmaceutical therapies currently in clinical trials are discussed. Furthermore, the advances in natural products as potential treatment for PAH are also updated.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33314936 DOI: 10.1021/acs.jmedchem.0c01093
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446